Alberto Bossi

🌟 Experience the latest of urology at #ScientificSummits 2024! Join us in 📍Leuven on May 24-25 for groundbreaking discussions on urothelial, prostate, and kidney cancer. Register now! 👇🔗scientificsummits.eu/conferences/sc…

@VedangMurthy @ZilliThomas @docpriyamvada ..."spaghetti" - like?

@ZilliThomas @docpriyamvada A bit all over the place, isn't it? 😀

Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials thegreenjournal.com/article/S0167-…

🏆 Join us in celebrating Bradley Pieters, who will be honored with the Iridium 192 Award at #ESTRO24! Don't miss his award lecture onsite in Glasgow: "Confidence through Certainty" 📅 Sunday 5 May 2024 🕑 14:15-14:40 👉 Read his interview: bit.ly/49MRdt9 #brachytherapy

@ChapinMD @uroegg @MDAndersonNews ...agree....Let s mention PROTECT to our patients: "no excess non-PCa mortality at 15 ys. for RT compared to RP"...perhaps at 25 ys?....🙂

@AlbertoBossial @uroegg @MDAndersonNews Population studies aren’t always reliable and clearly different then most major centers. I can also find pop data that says surgery far better OS than RT but we don’t believe that. But not here to argue that surgery has risks, indeed it does.

My sense is some men choose surgery over RT due to concerns over secondary malignancy. If you discuss secondary malignancies of RT (as I do), be fair and explain it appears to be an absolute risk of 0.5-1% at 25 years (many docs don't give risk estimate) auajournals.org/doi/full/10.10…

@ChapinMD @uroegg @MDAndersonNews

@AlbertoBossial @uroegg That’s not been our experience @MDAndersonNews, but I understand the consideration of an operative complication and possible death.

@ChapinMD @uroegg I tell them that the risk of developing a second cancer 25 ys after RT is slightly higher compared to the risk of dying 90 days after RP....

@uroegg I tell them a 1-2% increase depending on life expectancy. Often hear patients saying their doc told them 2-3x risk. I try an explain that if the lifetime risk is 0.5% and with RT it’s 1.5% both explanations correct, but one perhaps more misleading.

🆕Introducing the EuroBrachytherapy #Fellowship: an excellent opportunity to learn and gain hands on experience in a radiation oncology subspecialty. An initiative of the GEC-ESTRO education task force. 👉 Apply here: bit.ly/49YyviB #Brachytherapy #radonc

@Mat_Guc ...at 1250 Euro ??

Meeting about latest developments in Stereotactic Radiotherapy organized by Centre LEON BERARD 🙏 dear Vincent Grégoire for the kind invitation, your hospitality and for pushing #radonc forward !

@PBlanchardMD @TheLancetOncol @DrMLChua @ClairePetit19 ...nasopharyngeal cancer....in dogs?

Still some progress needed on automated e-mailing from #predatoryjournals... Delighted to be invited to submit to "Integrative Journal of Veterinary Biosciences" but they must have *slightly* misread our @TheLancetOncol article on chemotherapy for #NasopharyngealCancer...

We will have a blended mix of online and onsite practical teaching supported with lessons and case discussion of very experienced professionals in the field of #Brachytherapy. Peter Hoskin, José Luis Guinot, @ChargariC, Andrea Slocker Escarpa, Åsa Carlsson Tedgren, Mirjam Laman.

@CTuscanoMD ...don t trust Choline PET....Do a PSMA.....

A rare inguinal N met detected with a Choline PET in a pt with an early resistence to ADT+Enza ( 2.5 ng/mL PSA). Other nodes detected in pelvic echelons. ( Previously 36Gy/6 Fr. to prostate - Stampede and to a single pubic bone lesion). ❓ - Docetaxel - PET driven RT #radonc

Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Oral Relugolix is a Therapeutic Option with Similar Patient-reported HRQOL to Leuprolide! European Urology In Press authors.elsevier.com/sd/article/S03…

@StephenRameyMD @PaulSargos @abhiAsolanki ...l don't see HDR Brachy....

How should a recurrence in the prostate only after prior external beam radiation be treated? Most common answer at #ASTRO23 was … SBRT at 43%. @abhiAsolanki

On 25-26 Jan the next Amsterdam Brachy Academy workshop with support of @Elekta. The workshop is ideal for young doctors to learn about the first steps of #Brachytherapy. email:amsterdambrachycollege@amc.nl. Don’t miss this opportunity at @amsterdamumc. brachyacademy.com/wp-content/upl…

Spesso non ho condiviso la linea editoriale di @_MicroMega_, ma va riconosciuto il fatto che è sempre stata una voce di sinistra originale, coraggiosa ed eterodossa, come nel caso della denuncia dell'aggressione russa all'Ucraina. Mi abbonerò micromega.net/micromega-muor…

@DrYukselUrun @AmarUKishan @TiansterZhang @brookmans76 @NehaVapiwala @ChapinMD @Daniel_J_George @AarmstrongDuke @alison_tree @ProfPadhani @PBarataMD ...again and again....l remind you that the only Randomized Trial of RT versus Surgery PROTECT showed NO statistical difference in OS ....whatever definition of BCR you use NO higher mortality risk for RT compared to SURG...

🔍 New study sheds light on prostate cancer treatment outcomes! 🤔While biochemical recurrence is more common post-radical prostatectomy, the mortality risk is higher post-radiotherapy. 🩺 Rethinking our approach to BCR is crucial to optimize patient care and reduce overtreatment. 🚫 #prostatecancer #ProstateCancerAwarenessMonth @JAMANetworkOpen @OncoAlert @APCCC_Lugano @PCFnews @Tilki_De @piet_ost @AlbertoBossial @GGiannarini @Uromigos @urotoday @Uroweb @zklaassen_md @amerseburger doi:10.1001/jamanetworkopen.2023.32900

@UCDavisUrology @monda_steven ...l remind you that the only Randomized Trial in this space PROTECT showed NO excess non-PCa mortality for RT compared to Surg at 15 ys follow-up...so NO excess second cancers mortality for RT compared to Surg.....I am sick of replying to this sort of studies...

Secondary malignancy is a long term risk of radiation. Using the SEER registry, @monda_steven et al. found that the risk of developing and dying from bladder cancer is increased in patients with prostate cancer treated with radiation, compared to RP doi.org/10.1016/j.euf.…

Learn about localised, advanced, and metastatic #prostatecancer management, latest scientific evidence & future advancements. Engage in interactive case studies, journal clubs, & open discussions. Early fee until 12 July, register for our course now! ℹ bit.ly/3CMge8T

@cgratzke @declangmurphy @BertrandTOMBAL @GertMeerleer ....first analysis of PEACE 1 shows prostate RT delays the onset of Castration Resistance / Severe GU local symptoms IRRESPECTIVE of systemic TT and of disease burden...shall we discuss this with ALL denovo M+ pts?

@declangmurphy @BertrandTOMBAL @AlbertoBossial @GertMeerleer Really surprised how this recommendation can be derived based on PEACE1 data. If it is based on prevention of „complications“, one would have to better analyse micturition symptoms first. Even @AlbertoBossial mentioned „selected“ high volume patients, if I recall correctly…

#UroOnco23 Geert De Meerler recommending prostate RT on all patients, low and high volume, based on PEACE1 data from @AlbertoBossial . But Stampede show near significant OS detriment for high volume. To soon...

@brookmans76 @joniau ...which is the standard arm?....

Great presentation of #ARNEO results by @joniau #UroOnco23 Neoadjuvant treatment apa/ADT vs ADT prior to RP in #prostatecancer: BCR not sign. different yet + MRD does not seem to be a good surrogate for BCR. But: downstaging to pT2 was higher with apa/ADT + correlated with BCR